<DOC>
	<DOCNO>NCT00386360</DOCNO>
	<brief_summary>The primary purpose protocol evaluate sensitivity 3D-pQCT ( 3D-Peripheral Quantitative Computed Tomography ) technology detect minute change bone microarchitecture .</brief_summary>
	<brief_title>Study Effect Once Week Risedronate Microstructure Tibia Radius Using New Scanning Method</brief_title>
	<detailed_description>The 3D-pQCT equipment allow evaluation change occur within bone `` microarchitecture '' level , without need invasive bone biopsy . The primary objective evaluate sensitivity technology detect difference treat risedronate 35mg OAW ( week ) placebo . Early phase postmenopausal woman osteopenia choose rapid high level bone loss first year menopause .</detailed_description>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>cessation menstruation ( surgical natural ) 6 36 month prior study enrollment ; osteopenic must least 1 evaluable radius tibia , without history fracture ( traumatic atraumatic ) BMI ( body mass index ) 18 28 kg/m2 inclusive ; history generalize bone disease , include hyperparathyroidism , Paget 's disease bone , renal osteodystrophy , acquire congenital bone disease ; know condition would interfere assessment DXA ( dualenergy Xray absorptiometry ) either lumbar spine ( 3 nonevaluable lumbar vertebra lumbar spine L1 L4 ) femoral neck . clinical radiological evidence osteoporosis , atraumatic vertebral compression fracture ( * 20 % reduction anteriortoposterior middletoposterior height ratio ; 20 % reduction anterior , middle , and/or posterior height compare adjacent vertebra ) document spinal X ray history osteoporosisrelated atraumatic fracture hip wrist ; glucocorticoidinduced osteopenia ; previous bisphosphonate therapy ;</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>